Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

Inclusion Criteria:

   - Must have Genotype 1a, 1b, 4 or 6 HCV infection.

   - Documented clinical history compatible with chronic hepatitis C

   - HCV treatment-naïve or interferon/RBV-treatment relapsed (Part C)

   - Must agree to use an acceptable double method of birth control (one of which must be a
   barrier method) for at least 6 months after the last dose of study drugs.

Exclusion Criteria:

   - Female participants who are pregnant or breastfeeding.

   - Body Mass Index (BMI) > 36 kg/m2.

   - Co-infected with hepatitis B virus or human immunodeficiency virus (HIV).

   - History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC.

   - History or signs of decompensated liver disease: ascites, variceal bleeding, hepatic
   encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal
   hypertension or hepatic insufficiency.

   - Has one or more known primary or secondary causes of liver disease, other than
   hepatitis C

   - History of, or active, acute or chronic, liver or biliary injury due to drugs, toxins,
   non-HCV viral hepatitis, gallstones or other etiologies

   - Donated blood or had significant blood loss 30 days prior to dosing